Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women

TABLE 3

Average annual incidence rates of diabetes in tertiles of the troglitazone group defined by changes in SI or by changes in IVGTT insulin area between baseline and 3 months on trial

Tertile 1 Tertile 2 Tertile 3 P
Change in SI
 Median −0.09 0.99 2.28
 Range −2.13 to 0.44 0.54 to 1.41 1.43 to 7.67
 Annual diabetes incidence 9.8% 1.1%* 4.8% 0.04
Change in IVGTT insulin area
 Median −40 −1,813 −5,315
 Range 4,487 to −1,180 −1,238 to −3,053 −3,160 to −19,364
 Annual diabetes incidence 7.2% 7.8% 0.9% 0.05
  • Data are from 108 women randomized to troglitazone who had IVGTTs at baseline and 3 months on trial. P values among subgroups by log-rank test.

  • P < 0.05,

  • *

    * P < 0.01,

  • P < 0.001 vs. diabetes incidence in placebo group (log-rank test).

This Article

  1. Diabetes vol. 51 no. 9 2796-2803